Amalia Peix1, Ganesan Karthikeyan2, Teresa Massardo3, Mani Kalaivani2, Chetan Patel2, Luz M Pabon4, Amelia Jiménez-Heffernan5, Erick Alexanderson6, Sadaf Butt7, Alka Kumar8, Victor Marin9, Claudio T Mesquita10, Olga Morozova11, Diana Paez11, Ernest V Garcia12. 1. Nuclear Medicine Department, Institute of Cardiology, 17 No. 702, Vedado, CP 10 400, La Habana, Cuba. peix@infomed.sld.cu. 2. All India Institute of Medical Sciences, New Delhi, India. 3. Hospital Clínico Universidad de Chile, Santiago, Chile. 4. Fundación Valle del Lili, Cali, Colombia. 5. Hospital Juan Ramón Jiménez, Huelva, Spain. 6. Instituto Nacional de Cardiología Ignacio Chávez, Mexico, DF, Mexico. 7. Oncology and Radiotherapy Institute (NORI), Islamabad, Pakistan. 8. Dr. B L Kapur Memorial Hospital, New Delhi, India. 9. Fundación Cardioinfantil, Bogotá, Colombia. 10. Hospital Universitario Antonio Pedro, Niteroi, Brazil. 11. Nuclear Medicine and Diagnostic Imaging Section, International Atomic Energy Agency, Vienna, Austria. 12. Emory University, Atlanta, GA, USA.
Abstract
BACKGROUND: Placing the left ventricular (LV) lead in a viable segment with the latest mechanical activation (vSOLA) may be associated with optimal cardiac resynchronization therapy (CRT) response. We assessed the role of gated SPECT myocardial perfusion imaging (gSPECT MPI) in predicting clinical outcomes at 6 months in patients submitted to CRT. METHODS: Ten centers from 8 countries enrolled 195 consecutive patients. All underwent gSPECT MPI before and 6 months after CRT. The procedure was performed as per current guidelines, the operators being unaware of gSPECT MPI results. Regional LV dyssynchrony (Phase SD) and vSOLA were automatically determined using a 17 segment model. The lead was considered on-target if placed in vSOLA. The primary outcome was improvement in ≥1 of the following: ≥1 NYHA class, left ventricular ejection fraction (LVEF) by ≥5%, reduction in end-systolic volume by ≥15%, and ≥5 points in Minnesota Living With Heart Failure Questionnaire (MLHFQ). RESULTS: Sixteen patients died before the follow-up gSPECT MPI. The primary outcome occurred in 152 out of 179 (84.9%) cases. Mean change in LV phase standard deviation (PSD) at 6 months was 10.5°. Baseline dyssynchrony was not associated with the primary outcome. However, change in LV PSD from baseline was associated with the primary outcome (OR 1.04, 95% CI 1.01-1.07, P = .007). Change in LV PSD had an AUC of 0.78 (0.66-0.90) for the primary outcome. Improvement in LV PSD of 4° resulted in the highest positive likelihood ratio of 7.4 for a favorable outcome. In 23% of the patients, the CRT lead was placed in the vSOLA, and in 42% in either this segment or in a segment within 10° of it. On-target lead placement was not significantly associated with the primary outcome (OR 1.53, 95% CI 0.71-3.28). CONCLUSION: LV dyssynchrony improvement by gSPECT MPI, but not on-target lead placement, predicts clinical outcomes in patients undergoing CRT.
BACKGROUND: Placing the left ventricular (LV) lead in a viable segment with the latest mechanical activation (vSOLA) may be associated with optimal cardiac resynchronization therapy (CRT) response. We assessed the role of gated SPECT myocardial perfusion imaging (gSPECT MPI) in predicting clinical outcomes at 6 months in patients submitted to CRT. METHODS: Ten centers from 8 countries enrolled 195 consecutive patients. All underwent gSPECT MPI before and 6 months after CRT. The procedure was performed as per current guidelines, the operators being unaware of gSPECT MPI results. Regional LV dyssynchrony (Phase SD) and vSOLA were automatically determined using a 17 segment model. The lead was considered on-target if placed in vSOLA. The primary outcome was improvement in ≥1 of the following: ≥1 NYHA class, left ventricular ejection fraction (LVEF) by ≥5%, reduction in end-systolic volume by ≥15%, and ≥5 points in Minnesota Living With Heart Failure Questionnaire (MLHFQ). RESULTS: Sixteen patients died before the follow-up gSPECT MPI. The primary outcome occurred in 152 out of 179 (84.9%) cases. Mean change in LV phase standard deviation (PSD) at 6 months was 10.5°. Baseline dyssynchrony was not associated with the primary outcome. However, change in LV PSD from baseline was associated with the primary outcome (OR 1.04, 95% CI 1.01-1.07, P = .007). Change in LV PSD had an AUC of 0.78 (0.66-0.90) for the primary outcome. Improvement in LV PSD of 4° resulted in the highest positive likelihood ratio of 7.4 for a favorable outcome. In 23% of the patients, the CRT lead was placed in the vSOLA, and in 42% in either this segment or in a segment within 10° of it. On-target lead placement was not significantly associated with the primary outcome (OR 1.53, 95% CI 0.71-3.28). CONCLUSION: LV dyssynchrony improvement by gSPECT MPI, but not on-target lead placement, predicts clinical outcomes in patients undergoing CRT.
Authors: Jeroen J Bax; Theodore Abraham; S Serge Barold; Ole A Breithardt; Jeffrey W H Fung; Stephane Garrigue; John Gorcsan; David L Hayes; David A Kass; Juhani Knuuti; Christophe Leclercq; Cecilia Linde; Daniel B Mark; Mark J Monaghan; Petros Nihoyannopoulos; Martin J Schalij; Christophe Stellbrink; Cheuk-Man Yu Journal: J Am Coll Cardiol Date: 2005-12-20 Impact factor: 24.094
Authors: Jagmeet P Singh; Helmut U Klein; David T Huang; Sven Reek; Malte Kuniss; Aurelio Quesada; Alon Barsheshet; David Cannom; Ilan Goldenberg; Scott McNitt; James P Daubert; Wojciech Zareba; Arthur J Moss Journal: Circulation Date: 2011-03-07 Impact factor: 29.690
Authors: Ji Chen; Ernest V Garcia; Jeroen J Bax; Ami E Iskandrian; Salvador Borges-Neto; Prem Soman Journal: J Nucl Cardiol Date: 2011-08 Impact factor: 5.952
Authors: Nitish Badhwar; Jameze James; Kurt S Hoffmayer; John W O'Connell; Deanna Green; Teresa De Marco; Elias H Botvinick Journal: J Nucl Med Date: 2016-07-14 Impact factor: 10.057
Authors: Saara Sillanmäki; Jukka A Lipponen; Mika P Tarvainen; Tiina Laitinen; Marja Hedman; Antti Hedman; Antti Kivelä; Hanna Hämäläinen; Tomi Laitinen Journal: J Nucl Cardiol Date: 2018-02-08 Impact factor: 5.952
Authors: Aju P Pazhenkottil; Ronny R Buechel; Bernhard A Herzog; Rene N Nkoulou; Ines Valenta; Ursula Fehlmann; Jelena-Rima Ghadri; Mathias Wolfrum; Lars Husmann; Philipp A Kaufmann Journal: Eur J Nucl Med Mol Imaging Date: 2010-06-17 Impact factor: 9.236
Authors: Jeroen J Bax; Gabe B Bleeker; Thomas H Marwick; Sander G Molhoek; Eric Boersma; Paul Steendijk; Ernst E van der Wall; Martin J Schalij Journal: J Am Coll Cardiol Date: 2004-11-02 Impact factor: 24.094
Authors: Anna I Mishkina; Victor V Saushkin; Tariel A Atabekov; Svetlana I Sazonova; Vladimir V Shipulin; Samia Massalha; Roman E Batalov; Sergey V Popov; Konstantin V Zavadovsky Journal: J Nucl Cardiol Date: 2022-07-14 Impact factor: 3.872